Please login to the form below

Not currently logged in
Email:
Password:

Ardelyx

This page shows the latest Ardelyx news and features for those working in and with pharma, biotech and healthcare.

Ardelyx gets second kidney disease trial win for tenapanor

Ardelyx gets second kidney disease trial win for tenapanor

Drug hit primary and all secondary endpoints. California biotech Ardelyx has a second positive trial for its lead drug tenapanor in chronic kidney disease (CKD), as it waits for an FDA ... Shares in Ardelyx rocketed 72% on the back of the new study on

Latest news

  • Ardelyx buys back drug from AZ to 'accelerate development' Ardelyx buys back drug from AZ to 'accelerate development'

    Now, Ardelyx is paying $25m back to AZ in order to reclaim rights to the programme and "accelerate the clinical development path" for drug. ... Ardelyx still has a $200m partnership in place with Sanofi for NaP2b inhibitors used in the treatment of

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Deal Watch table for February 2014 Deal Watch table for February 2014

    201. Ardelyx (formerly Nteryx) / Sanofi. Licence. 1. NaP2b inhibitor programme for ESRD.

  • Pharma deals during October 2012 Pharma deals during October 2012

    In keeping with the trend seen with many other biotech deals, Ardelyx has an option to co-promote the product in the US. ... 572. Ardelyx / AstraZeneca. Licence. RDX5791 for end stage renal and chronic kidney disease and IBS-C (phase II).

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
certain health

Transforming the way health brands and companies communicate, we deliver creative science led, insight-driven solutions that give award winning results...

Latest intelligence

Dr Henry Skinner
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
By Henry Skinner, Chief Executive Officer of the AMR Action Fund...
Personalised medicine AI
How early-stage clinical research is facilitating the new wave of personalised medicines
By Jorg Taubel...
patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...